Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This is a predicted long non-coding RNA gene, annotated as "novel transcript, antisense to CXCL6". It is a non-protein-coding transcript defined based on its genomic position opposite to the CXCL6 gene. There is no published evidence supporting a direct biochemical, regulatory, or disease role, and it is not considered a drug target. Many such non-coding transcripts are identified via high-throughput sequencing and computational annotation pipelines, and most remain functionally uncharacterized. This Ensembl object (ENSG00000298131) should not be confused with the protein-coding chemokine gene CXCL6 (ENSG00000124875), which encodes an inflammatory chemokine (and is a recognized therapeutic target in inflammation, cancer, and infection). The query target here is a different locus—an uncharacterized non-coding transcript, not a canonical drug target gene.
None, as it is not a validated target for drug therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CXCL6.